GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cogent Biosciences Inc (NAS:COGT) » Definitions » 14-Day RSI

Cogent Biosciences (Cogent Biosciences) 14-Day RSI : 39.82 (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cogent Biosciences 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-28), Cogent Biosciences's 14-Day RSI is 39.82.

The industry rank for Cogent Biosciences's 14-Day RSI or its related term are showing as below:

COGT's 14-Day RSI is ranked better than
67.49% of 1575 companies
in the Biotechnology industry
Industry Median: 44.62 vs COGT: 39.82

Competitive Comparison of Cogent Biosciences's 14-Day RSI

For the Biotechnology subindustry, Cogent Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogent Biosciences's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cogent Biosciences's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Cogent Biosciences's 14-Day RSI falls into.



Cogent Biosciences  (NAS:COGT) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cogent Biosciences  (NAS:COGT) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Cogent Biosciences 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Cogent Biosciences's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogent Biosciences (Cogent Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Executives
Fairmount Funds Management Llc 10 percent owner, other: See Remarks 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Evan Kearns officer: Chief Legal Officer AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
John L. Green officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
John Edward Robinson officer: Chief Scientific Officer C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140
Christopher W. Cain director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Peter Evan Harwin director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Arlene Morris director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Todd Shegog director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Jessica Sachs officer: Chief Medical Officer C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Matthew Ros director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Andrew R Robbins director, officer: President and CEO C/O 3200 WALNUT ST, BOULDER CO 80301
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018

Cogent Biosciences (Cogent Biosciences) Headlines

From GuruFocus

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

By Stock market mentor Stock market mentor 02-01-2023